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Opioids create a neuroinﬂammatory response within the CNS,
compromising opioid-induced analgesia and contributing to vari-
ous unwanted actions. How this occurs is unknown but has been
assumed to be via classic opioid receptors. Herein, we provide di-
rect evidence that morphine creates neuroinﬂammation via the
activation of an innate immune receptor and not via classic opioid
receptors. We demonstrate that morphine binds to an accessory
protein of Toll-like receptor 4 (TLR4), myeloid differentiation pro-
tein 2 (MD-2), thereby inducing TLR4 oligomerization and trigger-
ing proinﬂammation. Small-molecule inhibitors, RNA interference,
andgeneticknockoutvalidatethe TLR4/MD-2complex asa feasible
target for beneﬁcially modifying morphine actions. Disrupting
TLR4/MD-2 protein–protein association potentiated morphine an-
algesia in vivo and abolished morphine-induced proinﬂammation
in vitro, the latter demonstrating that morphine-induced proin-
ﬂammation only depends on TLR4, despite the presence of opioid
receptors. These results provide an exciting, nonconventional
avenue to improving the clinical efﬁcacy of opioids.
protein–protein interaction | pain management therapy | drug discovery
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pioids, such as morphine, have been used to treat pain for
millennia. However, it is now well-documented that mor-
phine can create neuroinﬂammation in the CNS (1), which has
been linked to suppression of morphine analgesia as well as
enhancement of morphine-induced tolerance, dependence, and
reward associated with drug abuse (1–7). Although morphine-
induced neuroinﬂammation leads to the release of neuro-
excitatory, proinﬂammatory substances such as proinﬂammatory
cytokines, how morphine creates such neuroinﬂammation has
remained a mystery. Various studies have alternatively suggested
that such effects of morphine may either be via classic opioid
receptors or via an interaction somewhere along the intracellular
cascade activated by Toll-like receptor 4 (TLR4) signaling. Here
we provide direct evidence that morphine creates its neuro-
inﬂammatory effects (i) by binding to the TLR4 accessory pro-
tein, myeloid differentiation protein 2 (MD-2), and inducing
TLR4/MD-2 oligomerization and subsequent TLR4 signaling
activation in a similar fashion to the classic TLR4 ligand, LPS
(endotoxin); (ii) not via μ-opioid receptors, but through activa-
tion of TLR4 signaling; (iii) not via an interaction along the
intracellular signaling pathway of TLR4, but solely through
binding in a speciﬁc LPS-binding pocket of MD-2; and (iv) not
just via microglia but also via CNS endothelial cells, which are
exposed to the highest concentrations of blood-borne morphine
as it transits to the CNS. Genetic knockout of TLR4/MD-2
suppressed morphine-induced neuroinﬂammatory responses and
potentiated acute morphine analgesia in vivo, indicating that
blocking the TLR4/MD-2 association is sufﬁcient to suppress
morphine-induced neuroinﬂammation. Finally, we validated this
strategy of disrupting the TLR4/MD-2 complex using drug-like
small-molecule inhibitors that potentiate acute morphine anal-
gesia, thereby laying the groundwork for the development of
therapeutic TLR4-targeting drugs for improving the clinical
efﬁcacy of opioids.
Results
Morphine Binds to MD-2. X-raycrystalstructureoftheTLR4/MD-2/
LPS complex shows that LPS binds to a hydrophobic pocket on
MD-2 and induces oligomerization of the TLR4/MD-2 complex
(8), forming a (TLR4/MD-2)/(TLR4/MD-2) heterotetramer and
facilitating signal transduction (9). Human MD-2 was expressed
and puriﬁed after the methods previously reported (8). The pre-
pared protein was shown to fold properly by circular dichroism
spectroscopy (SI Appendix,F i g .S 1A and B) with a melting tem-
perature(Tm)of≈80°C,whichisconsistentwithpreviousliterature
reports (10). We previously demonstrated that MD-2 produced in
thisfashioneffectivelybindsLPS(11).Tofurther demonstratethat
the prepared MD-2 protein retains its ligand-binding activity, we
tested its binding with a well-documented MD-2 ligand, curcumin
(12, 13). A Kd of 0.55 ± 0.36 μM was obtained (SI Appendix,F i g .
S1C), which is comparable to the literature value (13).
Prior observations have suggested that morphine can induce
neuroinﬂammation in vivo (14). To test whether morphine may
functionally mimic LPS, we ﬁrst tested whether morphine binds
to human MD-2. Biotin-labeled morphine was synthesized using
our previously developed method (SI Appendix, Fig. S2) (15).
The biotin tag was attached via a ﬂexible-PEG linker to the 3′
hydroxyl group that has been shown not to interfere with the
morphine-induced proinﬂammatory activation (15). Various
concentrations of biotinylated morphine then were immobilized
on a streptavidin-coated plate as the capturing probe in an
ELISA. As shown in Fig. 1A, morphine bound to human MD-2
in a concentration-dependent manner. We titrated MD-2 into
streptavidin-coated plates in the presence of 10 μM morphine.
As shown in Fig. 1B, human MD-2 was captured in a concen-
tration-dependent manner. By contrast, the binding to a negative
control (protein A) was negligible, indicating that the morphine–
MD-2 binding is speciﬁc. Additionally, LPS was found to com-
pete with immobilized morphine for binding to MD-2 (Fig. 1C).
Fig. 1D shows that, when MD-2 was immobilized on plates,
biotinylated morphine bound to MD-2 in a concentration-de-
pendent manner, whereas morphine showed little binding to the
control, BSA. Further, LPS antagonized biotinylated morphine
binding to human MD-2 immobilized on the ELISA plate (Fig.
1E), which is consistent with the result observed in Fig. 1C.
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YMorphine and MD-2 binding was also directly determined by
using a monoclonal antibody that speciﬁcally recognizes apoMD-
2 but not MD-2 with bound LPS (16). This assay detected de-
creased antibody binding to MD-2 in the presence of morphine
(Fig. 1F). As a comparison, roxithromycin, a natural product used
as a negative control in previous reports (SI Appendix, Fig. S3)
(17), showed no MD-2 binding activity. As shown in Fig. 1G,
morphine was found to compete with biotin-LPS immobilized on
the plate for binding to MD-2, suggesting that morphine binds to
the LPS binding pocket of MD-2, whereas roxithromycin showed
no inhibition. However, roxithromycin (SI Appendix,F i g .S 3 )
shares little structural similarity with morphine (SI Appendix,F i g .
S4A). We therefore used the morphine metabolite morphine-6-
glucuronide (M6G; SI Appendix, Fig. S4B) as a negative control
in the binding assays, because it has previously been shown to not
activate the TLR4 pathway (6, 18). Fluorescence probe curcumin
binds to MD-2, and its ﬂuorescence intensity enhances when
binding to MD-2 (13). As shown in Fig. 1H, morphine caused
a concentration-dependent decrease of curcumin ﬂuorescence
from the curcumin–MD-2 complex, suggesting that morphine
replaces curcumin binding to MD-2. Compared with morphine,
M6G induced negligible decrease in curcumin ﬂuorescence, again
supporting that morphine rather than M6G interacts with MD-2.
By ﬁtting the binding curve to a one-site competitive model, we
calculated the Ki value of 4.3 ± 3.3 μM for morphine competing
with curcumin for MD-2 binding.
Morphine Induces TLR4 Oligomerization. Next, we tested whether
morphine binds to MD-2 on the cell surface and induces TLR4
oligomerization. HEK Blue hTLR4 cells, which overexpress the
human TLR4 and MD-2, were stimulated with morphine. Cell
lysates were subjected to immunoprecipitation with morphine-
speciﬁc antibody and immuno-detected by MD-2 antibody. As
shown in the Fig. 2A, MD-2 was coimmunoprecipitated with
morphine, showing that morphine interacts with MD-2 in a
whole-cell environment.
The binding of LPS to MD-2 induced the oligomerization of
TLR4 (SIAppendix,Fi g.S5 ),facilitating TLR4 signaling(9). Totest
whether morphine induced TLR4 receptor oligomerization, Ba/F3
Fig. 1. Biophysical characterizations of morphine binding to human MD-2.
(A) Different concentrations of biotin-morphine were coated onto strepta-
vidin-precoated plate as the probe. Human MD-2 (10 μg/mL, protein A
tagged) was added, and the morphine-bound MD-2 was detected by IgG-
HRP conjugate. Absorbance with 40 μM biotin-morphine was set as 100%.
(B) Biotin-morphine (10 μM) was coated onto streptavidin precoated plate.
Different concentrations of human MD-2 were added, and the morphine-
bound MD-2 was detected by IgG-HRP conjugate. Protein A was used as the
negative control. Absorbance with 40 μg/mL MD-2 was set as 100%. (C), 10
μM of biotin-morphine was coated onto streptavidin-precoated plate. Hu-
man MD-2 (40 μg/mL) and different concentrations of LPS were added. The
morphine-bound MD-2 was detected by IgG-HRP conjugate. Absorbance
with 0 μg/mL LPS was set as 100%. (D) Human MD-2 (10 μg/mL) or BSA (used
as the control) was coated onto the plate. Different concentrations of biotin-
morphine were added, and the bound morphine was detected by strepta-
vidin conjugated with HRP. Absorbance with MD-2 in the presence of 2 μM
biotin-morphine was set as 100%. (E) Human MD-2 (10 μg/mL) was coated
onto the plate. Biotin-morphine (4.0 μM) and different concentrations of LPS
were added, and the bound morphine was detected by streptavidin conju-
gated with HPR. Absorbance with 0 μg/mL LPS was set as 100%. (F) MD-2
capturing antibody (2 μg/mL) was coated onto the plate. MD-2 (5 μg/mL;
protein A tag was removed) and different concentrations of morphine or
roxithromycin (used as the control) were added. Anti-MD-2 antibody 9B4
(0.1 μg/mL), which speciﬁcally recognizes apoMD-2, was added. MD-2 with-
out morphine bound was detected by HRP-coupled secondary antibody.
Absorbance with 0 μg/mL morphine or roxithromycin was set as 100%. *P <
0.05 vs. roxithromycin control group. (G) Biotin-LPS (0.1 μg/mL) was coated
onto streptavidin-precoated plate as the probe. Human MD-2 (10 μg/mL) and
different concentrations of morphine were added. The LPS-bound MD-2 was
detected by IgG-HRP conjugate. Absorbance with 0 μg/mL morphine or
roxithromycin was set as 100%. (H) Morphine replaced curcumin binding to
MD-2. Different concentrations of morphine or M6G were titrated into MD-2
(0.5 μM). Curcumin (0.5 μM) was added as the extrinsic ﬂuorescence probe.
The excitation wavelength was set at 430 nm, and the ﬂuorescence signal at
493 nm was plotted against the titrated morphine concentration. Fluores-
cence intensity of curcumin–MD-2 complex in the absence of morphine
was set as 100%. Data ﬁtting to a one-site competitive model gives a Ki of
4.3 ± 3.3 μM.
Fig. 2. Morphine induces TLR4 oligomerization and activates TLR4 signal-
ing. (A) Morphine bound to MD-2 in a cellular environment. HEK Blue hTLR4
cells, which overexpress the human TLR4 and MD-2, were treated with
morphine (300 μM) for 12 h, and cell lysates were immunoprecipitated by
morphine antibody and then detected by Western blotting by MD-2 anti-
body. GAPDH served as the cell lysates input control. (B) Morphine-induced
TLR4 receptor oligomerization. Ba/F3 cells simultaneously overexpressing
human TLR4-Flag, human TLR4-GFP, human CD14, and human MD-2 were
stimulated with morphine (300 μM) for 72 h. Cells were then subjected to
immunoprecipitation with anti-Flag antibody and immunoprobing with
anti-GFP antibody (Upper) and anti-Flag antibody (Lower). (C and D) Struc-
tural comparison of apo- and ligand-bound MD-2. The ligands are shown in
a ball-and-stick presentation. X-ray crystal structure of apoMD-2 (cyan; PDB
ID 2E56) superimposed with (C) X-ray crystal structure of the LPS-bound MD-
2 (pink; PDB ID 3FXI) or (D) morphine-bound MD-2 (yellow) derived from
atomic molecular dynamics simulation.
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as well as human CD14 and human MD-2 (19), were stimulated
with morphine. Cell lysates were subjected to immunoprecipitation
withanti-Flag antibodyand immuno-detectedbyanti-Flagand anti-
GFP antibodies. As shown in Fig. 2B, upon stimulation with mor-
phine, the coprecipitation of TLR4-GFP and TLR4-Flag signiﬁ-
cantly increased compared with the barely detectable basal level
observed in the control sample. The data imply that morphine,
similartoLPS,inducedTLR4oligomerization,possiblyinadimeric
form as previously documented (8).
X-ray crystallographic analyses of apoMD-2 and LPS-bound
MD-2 indicated that the binding of LPS induces conformational
changes of MD-2, primarily in the F126 loop region (8, 20).
Residue F126 is located in the core of the (TLR4/MD-2)/(TLR4/
MD-2) oligomerization interface and initiates structural changes
in MD-2 upon LPS binding. These conformational changes fa-
cilitated hydrogen bonds and electrostatic interactions between
the F126 loop residues of MD-2 and a second copy of TLR4,
stabilizing the dimeric (TLR4/MD-2)/(TLR4/MD-2) hetero-
tetramer complex (21). Mutation of F126 and the surrounding
residues in MD-2 blocked LPS-induced oligomerization (8).
Comparison of the dihedral angles of the residues in the F126
loop of the apoMD-2 [Protein Data Bank (PDB) ID 2E56] and
LPS–MD-2 (PDB ID 3FXI) structures showed variation of at
least 100° for the backbone dihedral angles of residues K122,
G123, K125, and F126. Further inspection of side-chain dihedral
angles showed variation of at least 100° for K125 and K128, in-
dicating that these residues were affected most by the LPS
binding. To gain insight into how morphine possibly affects MD-
2 structurally, we conducted molecular dynamics simulation us-
ing fully atomistic models of morphine and MD-2 in an implicit
solvent. A total of 3 ns of simulation time were performed, and
the structural changes in the F126 loop were examined (Fig. 2 C
and D). These ligand-induced conformational changes were also
monitored by the φ-ψ backbone dihedral angles (SI Appendix,
Fig. S6) and the χ1-χ2 side-chain dihedral angles (SI Appendix,
Fig. S7) extracted from the simulation trajectory. It was observed
that residues I124, K125, F126, and S127 underwent large
transitions of their backbone dihedral angles, whereas residues
K122, I124, K125, and S127 showed prominent shifts in the
orientation of their side chains. Of these, K122, K125, and F126
were the residues that also showed large differences in the
apoMD-2 and LPS-bound MD-2 structures. These observations
suggested that morphine, similar to LPS, induced MD-2 con-
formational change in the F126 loop, resulting in oligomeriza-
tion of the TLR4/MD-2 complex.
Morphine Triggers Proinﬂammation Responses in Immunocompetent
Cells. To demonstrate that morphine induces proinﬂammatory
responses in TLR4-expressing nonneuronal cells, the effect of
morphine on TLR4-expressing CNS endothelial cells (22) was
investigated. To eliminate confounding effects of μ-opioid re-
ceptor binding of (-)-morphine in these primary CNS endothelial
cells, (+)-morphine, which activates TLR4 signaling (5) but has
no μ-opioid receptor activity (23), was used. Using biophysical
methods, we have conﬁrmed that (+)-morphine indeed showed
binding afﬁnity comparable to MD-2 with (-)-morphine (SI Ap-
pendix, Fig. S8). Further, (+)-morphine similarly induces TLR4
oligomerization (SI Appendix,F i g .S 9 ). In-cell Western results
showed that LPS and (+)-morphine both caused dose-dependent
increases in p38 phosphorylation during 30 min treatment, as well
as dose-dependent increases in ERK phosphorylation (SI Ap-
pendix, Fig. S10). The data showed that morphine behaved like
LPS in activating the TLR4 pathway and induced rapid phos-
phorylation of the MAP kinases p38 and ERK in primary CNS
endothelial cells documented to express TLR4 (22). Quantitative
RT-PCR (qRT-PCR) was also performed to investigate the effect
of (+)-morphine and LPS on expression of mRNA for TLR4,
MD-2, and downstream proinﬂammatory cytokine IL-1β (Fig. 3
and SI Appendix, Fig. S11). In the presence of complex FBS
medium, 100 μM (+)-morphine, similar to LPS, potently in-
creased IL-1β mRNA in endothelial cells at 2 h, with a gradual
decline in IL-1β mRNA expression by 24 h. Morphine and LPS
also each increased TLR4 and MD-2 mRNA expression over
time. LPS-RS, a structural analog of LPS and a potent LPS an-
tagonist that targets MD-2 (8, 24, 25) and inhibits TLR4 signaling
(9, 24), attenuated morphine and LPS-induced IL-1β and TLR4
mRNA elevations. CLI-095, an intracellular TLR4 antagonist
Fig. 3. Isolated primary CNS en-
dothelial cells incubated with
(+)-morphine induce proinﬂam-
matory mediator (IL-1β) and TLR
(TLR4 and the coreceptor MD-2)
mRNA up-regulation after 2-h,
4-h, and 24-h incubations. (A)
(+)-Morphine (100 μM) increased
IL-1β mRNA at 2 h with a gradual
decline in IL-1β mRNA expression
by 24 h. (B and C) Gradual in-
crease in TLR4 and MD-2 mRNA
expression over time with the
100 μM (+)-morphine compared
with vehicle control. (+)-Mor-
phine (100 μM) was coincubated
for 24 h with 10 ng/mL LPS-RS,
a competitive TLR-4 antagonist, 1
μM CLI-095, an intracellular TLR4
antagonist, and 1 μM BAY11-
7082, an IκB-α inhibitor. LPS-RS
signiﬁcantly attenuated (+)-mor-
phine-induced IL-1β (D) and TLR4
(E) mRNA. CLI-095 signiﬁcantly
attenuated TLR4 (E) and MD-2 (F)
mRNA. BAY11-7082 signiﬁcantly
attenuated IL-1β (D), TLR4 (E),
and MD-2 (F) mRNA. Experimental procedures are described in SI Appendix, SI Materials and Methods. n = 6 per group per time interval. *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001. One-way ANOVA compared with vehicle control, with Bonferroni post hoc comparisons.





















Yacting on Cys747 of TLR4 (26), signiﬁcantly attenuated morphine
and LPS-induced TLR4 and MD-2 mRNA overexpression. IκB-α
is an inhibitor of NF-κB activation and an important downstream
regulator of TLR4 signaling pathway (9). IκB-α inhibitor BAY11-
7082 also signiﬁcantly attenuated morphine- and LPS-induced
IL-1β, TLR4, and MD-2 mRNA overexpression.
TLR4/MD-2 Complex Mediates Morphine-Induced Proinﬂammation.
The association of TLR4 and MD-2 is essential for downstream
activation of NF-κB and production of proinﬂammatory cytokines
(9). NF-κB activation and up-regulation of proinﬂammatory
cytokines were used to monitor TLR4 activation. As shown in SI
Appendix, Fig. S12A, morphine induced NF-κB activation in
a dose-dependent manner in BV-2 microglia, macrophage-like
immunocompetent cells in the CNS that express TLR4 (1, 14).
The competitive inhibitor curcumin (SI Appendix, Fig. S12B) and
LPS-RS (SI Appendix,Fig. S12C), which by themselves showed no
inﬂuence on NF-κB activity (SI Appendix, Fig. S13), suppressed
morphine-induced NF-κB activation in a dose-dependent man-
ner. Furthermore, the MD-2 binding agent curcumin inhibited
morphine-induced IκB-α degradation (SI Appendix, Fig. S14A).
Morphine stimulation also increased the NF-κB p65 protein ex-
pressionlevel,aneffectthatwasblockedbytheMD-2competitive
inhibitor curcumin (SI Appendix, Fig. S14B). These data con-
ﬁrmed that morphine did not activate NF-κB beyond the TLR4/
MD-2 complex, suggesting a unique strategy to suppress mor-
phine-induced inﬂammation by targeting the TLR4/MD-2 pro-
tein complex. Importantly, in addition, because these microglia
also express opioid receptors (27), these data demonstrate that
the morphine-induced proinﬂammatory responses are not medi-
ated by opioid receptors because the response was abolished by
blocking only MD-2.
Next, RNAi was performed to demonstrate that an intact
TLR4/MD-2 complex is essential for CNS immunocompetent
cell activation. We optimized siRNA transfection procedures so
as to attain ≈60% speciﬁc knockdown efﬁciency in BV-2
microglia for both TLR4 and MD-2, as conﬁrmed by Western
blot analysis (SI Appendix, Fig. S15). Proinﬂammatory factors
such as nitric oxide (NO), IL-1β, and TNF-α were monitored as
indicators of TLR4 activation (1). As shown in SI Appendix, Fig.
S12D, knockdown of MD-2 or TLR4 by RNAi suppressed
morphine-induced NO production to a signiﬁcant extent. Fur-
ther, stimulation with morphine increased production of the
proinﬂammatory cytokines IL-1β and TNF-α, which was abol-
ished by knocking down either TLR4 or MD-2 (SI Appendix, Fig.
S12 E and F). In the absence of morphine, RNAi suppression of
MD-2 or TLR4 slightly reduced the background level of proin-
ﬂammatory factors, including IL-1β and TNF-α (SI Appendix,
Fig. S16). It should be noted that no cell proliferation inhibition
was observed at the concentrations of morphine used in these
experiments (SI Appendix, Fig. S17). Taken together, RNAi
knockdown of either TLR4 or MD-2 suppresses morphine-in-
duced proinﬂammatory responses, suggesting that TLR4/MD-2
mediated TLR4 activation and provides a target for small-mol-
ecule regulation. Also importantly, these results provided further
support that morphine neither activates TLR4 signaling pathway
beyond MD-2 nor creates neuroinﬂammatory responses via the
classic opioid receptors coexpressed on BV-2 microglial cells.
MyD88-Dependent TLR4 Signaling Is Involved in Morphine Analgesia.
Knockout mice for TLR4 and MyD88, a critical downstream
effector of TLR4 (9), were used separately to assess the in-
volvement of TLR4 and the MyD88-dependent signaling cascade
in acute morphine analgesia over a range of concentrations. Prior
studies have demonstrated that morphine-induced neuroinﬂam-
mation suppressed acute morphine analgesia (4, 14, 28, 29).
Hence, we predicted that knocking out TLR4 or MyD88 should
potentiate acute morphine analgesia if morphine-induced neuro-
inﬂammatory responses are via this pathway. Pain responsivity
was compared for the knockout strains and their respective wild-
type controls dosed by i.p. injection of morphine, ranging from
no analgesia to maximal analgesia. As expected, increasing doses
of morphine resulted in signiﬁcant increases in hotplate latencies
in all strains. Further analysis of the morphine dose–response
curves revealed a main TLR4 and MyD88 effect whereby both
TLR4- and MyD88-knockout mice achieved signiﬁcantly longer
hotplate latencies compared with their respective wild-type
controls. In both cases there was a 2.2-fold leftward shift in the
knockout morphine analgesic dose–response curve (ED50 wild-
type 2.8 mg/kg vs. TLR4-knockout 1.2 mg/kg; ED50 wild-type 11.9
mg/kg vs. MyD88-knockout 5.4 mg/kg) compared with wild-type
mice (SI Appendix, Fig. S18). In addition, both knockout strains
had a signiﬁcantly altered dose–response Hill slope compared
with wild-types.
After behavioral testing, wild-type and TLR4-knockout mice
spinal cord samples were collected after a range of morphine
doses to enable quantiﬁcation of in vivo signaling via the TLR4
cascade. Samples were analyzed for downstream TLR4 MAP
kinase phosphorylation. After morphine administration, there
was a main strain (P < 0.01) and dose effect (P < 0.001) and
interaction (P < 0.01) as assessed using p38. Post hoc analysis
revealed that morphine signiﬁcantly increased p38 phosphory-
lation at doses of 0.1 and 50 mg/kg (P < 0.05; SI Appendix, Fig.
S19A) compared with TLR4-knockout mice. Analysis also
revealed a main strain and dose effect (P < 0.05) for JNK,
whereas ERK displayed a main strain effect (P < 0.05) and in-
teraction (P < 0.001) (SI Appendix, Fig. S19 B and C). Together,
the data demonstrated that the MyD88-dependent TLR4 sig-
naling is involved in morphine analgesia.
Small-Molecule Inhibitors of the TLR4/MD-2 Association Potentiate
the Efﬁcacy of Morphine. Having shown that disruption of TLR4/
MD-2 was sufﬁcient to regulate the morphine-induced proin-
ﬂammatory responses, we continued the investigation using
drug-like, small-molecule agents. These small-molecule agents
may validate the TLR4/MD-2 complex as a potential target for
drug development, laying the groundwork for a new strategy to
potentiate morphine analgesia (Fig. 4A). Two previously iden-
tiﬁed small-molecule probes that selectively inhibited the TLR4/
MD-2 interactions (30, 31) were used to study their effects in
morphine-induced proinﬂammatory response both in vitro and
in vivo. Compound 1 (SI Appendix, Fig. S20) has been identiﬁed
to target TLR4, and compound 2 (SI Appendix, Fig. S21) was
identiﬁed as the MD-2 antagonist (30, 31). To biophysically
characterize compounds 1 and 2 and their targets interactions,
competitive ELISAs were performed. As shown in the Fig. 4B,
compound 1 competed against MD-2-I, a 17-residue peptide
derived from the TLR4-binding region of MD-2, which tightly
binds to TLR4 (11, 32). By contrast, negative control compound
3 (SI Appendix, Fig. S20), a structural analog to 1, show no in-
hibitory effects to MD-2-I binding to TLR4 (Fig. 4B). Similarly,
compound 2 competed against morphine binding to MD-2 (Fig.
4B). It should be noted that racemic form of 1 was used in these
studies because previous reports showed that the stereocenter in
1 did not affect its TLR4 inhibition activities (31).
The in vitro inhibitory effects of compounds 1 and 2 on
morphine-induced microglial cell activation were investigated.
Treatment of BV-2 cells with morphine elevated the IL-1β
expression level, indicative of activation of TLR4 signaling.
Coincubation of morphine with compound 1 or 2 abolished
morphine-induced IL-1β production to the background level
(Fig. 4C). In contrast, negative control compound 3, an inactive
analog to 1, did not show any signiﬁcant reduction of IL-1β ex-
pression (SI Appendix, Fig. S22). These results demonstrated that
small-molecule inhibitors of TLR4 signaling reduce morphine-
induced proinﬂammatory responses.
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pounds 1 and 2 were able to potentiate the analgesic effect of
morphine in vivo. The Hargreaves test (33) was used to measure
pain response via the time taken to observe radiant heat-induced
withdrawal responses by tails of unrestrained rats. Before drug
administration, two readings were recorded for controls. After
these baseline measurements, drugs were injected intrathecally,
and the rats’ responses to radiant heat were assessed across a 3-h
time course. Whereas compounds 1 (Fig. 4D) and 2 (Fig. 4E)
had no effect on pain responsivity in the absence of coadminis-
tered morphine, they robustly potentiated the acute analgesic
effects of morphine such that the rats exhibited the maximal
analgesia recordable on the test, presumably by inhibiting mor-
phine-induced proinﬂammatory response in the CNS. These
results indicated that TLR4/MD-2 was a valid target for the
regulation of opioid-induced TLR4 activation in vivo.
Using a knockout mouse model, we further demonstrated that
the TLR4 signaling pathway is the target for potentiating mor-
phine analgesia. Pain responsivity was compared for wild-type vs.
TLR4-knockout mice dosed via i.p. injection of morphine at
a dose causing low analgesia in the absence of TLR4 inhibitors
(34). Compounds 1 and 2 were highly effective in potentiating
analgesia in wild-type mice, as expected if TLR4 mediated sup-
pression of morphine analgesia via morphine-induced neuro-
inﬂammation. In contrast, TLR4-knockout mice were unaffected
by treatment of morphine coadministered with compounds 1 or 2
(Fig. 4 F and G), again, as expected if morphine was acting only
via TLR4. These data provided ﬁrm evidence that 1 and 2
exerted their analgesic effect by targeting TLR4/MD-2. Last,
compounds 1 and 2 were administered in these experiments with
negligible cytotoxicity (SI Appendix, Fig. S23).
Discussion
It is now well accepted that opioids such as morphine induce
neuroinﬂammatory responses within the brain and spinal cord,
which potently dysregulate the actions of opioids. Although it
was long assumed that opioid-induced neuroinﬂammation must
be mediated via activation of classic opioid receptors, recent data
from Hutchinson et al. contested this assumption. Their data
demonstrated that morphine-induced CNS neuroinﬂammation
was created by nonclassic (nonstereoselective) opioid actions
that cannot be explained as being mediated by classic opioid
receptors (1, 4–6, 14, 35). Although nonstereoselective effects
demonstrate that some receptor, enzyme, or second messenger
other than classic, stereoselective opioid receptors must underlie
opioid-induced neuroinﬂammatory effects, how this occurs was
unknown. Although follow-on studies suggested that opioids
were likely interacting somewhere along (at least) the TLR4
signaling pathway, how and where this interaction was occurring
remained a mystery. Had opioids interacted directly with various
intracellular signaling elements of the TLR4 pathway that are
also downstream of receptors other than TLR4, this would have
indicated that morphine impacts multiple signaling cascades, as
do direct modulators of p38, NF-κB, etc. In contrast, the present
series of multidisciplinary studies provided converging lines of
evidence that morphine activates TLR4 signaling, not via inter-
actions along the intracellular signaling cascade, but rather
explicitly and only via LPS-like interactions with TLR4’s cor-
eceptor MD-2. Thus, opioid-induced neuroinﬂammation is via
a highly selective extracellular interaction affecting solely MD-2.
Further, these studies provided converging lines of evidence that
opioid receptors do not mediate opioid-induced neuroinﬂam-
matory responses because blocking only MD-2 blocks morphine-
induced neuroinﬂammation despite the simultaneous expression
of opioid receptors in the same cells.
Developing highly speciﬁc small-molecule inhibitors of TLRs is
a dynamic research area in drug discovery owing to the great dis-
ease relevance of these innate immune receptors. A previously
used strategy involved developing LPS-mimicking antagonists of
TLR4 (e.g., LPS-RS). Nonetheless, agents derived from this
Fig. 4. TLR4/MD-2 antagonists abolish morphine-induced proinﬂammatory
activation in vitro and in vivo. (A) A strategy of potentiating opioid analgesia
by disrupting the nonneuronal TLR4/MD-2 complex. Upper: Opioids activate
CNS immunocompetent cells by triggering a signal transduction cascade
mediated by TLR4 (dimeric form in complex with MD-2). This results in the
release of the cytokine intercellular mediator IL-1β and other proin-
ﬂammatory factors, which suppresses the desired opioid-induced neuronal
analgesic effect. Lower: In the presence of TLR4-signaling antagonists such as
inhibitors of the critical TLR4/MD-2 interaction, CNS immunocompetent cells
remain in the resting state. Opioids (red star) then show higher analgesic
efﬁcacy by binding solely to opioid receptors (orange hexagon) on neurons.
(B)CompetitiveELISAbinding.Compound1competesagainst MD-2-Ipeptide
bindingtoTLR4,andcompound2competesagainstmorphinebindingtoMD-
2. Negative control compound 3, which shares similar structure with com-
pound 1, showed no apparent binding to TLR4. (C) TLR4/MD-2 antagonists
inhibited morphine-induced IL-1β overproduction in microglial BV-2 cells. BV-
2 cells were incubated in the presence of morphine (200 μM), morphine (200
μM), and 10 μM of compound 1 or 2. Cell lysates from BV-2 cells were assayed
for IL-1β protein by ELISA. (D and E), TLR4/MD-2 antagonists 1 (D) and 2 (E)
potentiated the acute intrathecal morphine analgesia. After predrug (base-
line) assessment of responsivity to radiant heat (Hargreaves test), rats re-
ceived intrathecal morphine (1 μL, 15 mg/mL), 1/2 (1 μL, 30 mM), or the
combination of morphine and 1/2 at same doses. Data are expressed as per-
centmaximumpotentialeffect(MPE).Dataaremeansfromsixanimals.(Fand
G) Selectivity of potentiation of morphine analgesia by TLR4/MD-2 antago-
nists 1 (F) and 2 (G) in wild-type vs. TLR4 knockout mice. It should be noted
herethat wechoseamorphinedosethatproducedlowanalgesia inwild-type
mice (has greater analgesia in TLR4 KO mice). Therefore, behavioral tests
were not hampered by the ceiling cutoff. After predrug (baseline) assessment
of responsivity to radiant heat (Hotplate test), mice received i.p. 1 (82 mg/kg)
or 2 (153 mg/kg), followed 10 min later by i.p. morphine (2.5 mg/kg). n =6
animals for morphine groups and n = 3 for small molecules alone. It should be
note here that morphine used here is (-)-morphine.





















Yapproach suffer from the signiﬁcant shortcoming of poor phar-
macological properties (e.g., poor brain–blood barrier permeabil-
ity). A recent example is eritoran, an LPS mimetic, failed in phase
III clinical trials (36). An alternative strategy is to design small-
molecule inhibitors to target downstream receptors of TLR4. Us-
ing this strategy, several TLR4 antagonists have been developed
although, to the best of our knowledge, none has successfully ad-
vanced through late-stage clinical trials. TAK-242 (resatorvid), the
most successful TLR4-binding small-molecule antagonist, reached
phase III clinical trials as an antisepsis agent, but studies were re-
cently discontinued owing to a failure to suppress cytokine levels in
patients despite showing promising preclinical efﬁcacy in animal
models (37). These results might have implied that the current
approaches to targeting the TLR4 receptor are ﬂawed. Novel strat-
egies to regulate the innate immune response are urgently needed.
In this present study, we attempted a unique approach for
optimization of opioid therapies by selectively targeting the
TLR4/MD-2 complex. TLR4/MD-2 is required by morphine-in-
duced TLR4 activation, and its disruption abolished the down-
stream neuroinﬂammation. Among all members of the TLR
protein family, TLR4 is the only one that has been conﬁrmed to
form an active heterodimer with MD-2 [although there are still
ongoing debates whether TLR2 also binds to MD-2 (38)]. Spe-
ciﬁc inhibition of the TLR4/MD-2 association might eventually
lead to selective drug candidates to target the TLR4 signaling
pathway without affecting the normal functions of other ho-
mologous TLR protein family members.
In summary, we have demonstrated that morphine bound to
MD-2, induced TLR4 oligomerization, and activated TLR4 sig-
naling, in a fashion similar to that of LPS. RNAi, in vivo knockout,
and small-molecule inhibitors of the TLR4/MD-2 complex sup-
pressed morphine-induced immunocompetent cells activation in
vitro and in vivo, validating TLR4/MD-2 complex as a target for
therapeutic development to improve the current opioid-based
pain management therapies. Optimized small-molecule inhibitors
of TLR4-mediated immunocompetent cells activation may pro-
vide novel drug candidates to enhance opioid efﬁcacy and possibly
improve safety.
Materials and Methods
SI Appendix, SI Materials and Methods provides complete experimental
methods. It includes reagents and details of MD-2 and TLR4 expression and
puriﬁcation, chemical synthesis, ELISAs, ﬂuorescence titration, morphine/MD-
2 molecular dynamics simulation, qRT-PCR and Western blot, coimmuno-
precipitation of MD-2 with morphine, TLR4 receptor oligomerization assay,
dual luciferase reporter assay, secreted alkaline phosphatase assay, RNAi, cell
proliferation assay, CNS endothelial cell isolation and culture, in-cell Western
blots, behavioral assessment of responsivity to radiant heat in rats, and be-
havioral assessment of responsivity to radiant heat in TLR4-knockout and
wild-type mice. Methods for statistical analysis are also included.
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